Company Profile

Lucira Health Inc (AKA:Diassess Inc)
Profile last edited on: 5/5/2022            CAGE: 5ZRT5            UEI: LYVKL8XMHKF1

Disposable test kits to detect RNA and DNA of infectious diseases
Year Founded
2012
1st Awd Year
2012
Latest Award
2022
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

442 Stanley Hall
Berkeley, CA 94720
   (814) 574-1546
   info@lucirahealth.com
   www.diassess.com
Multiple Locations:   
Congressional District:   13
County:   Alameda

Public Profile

Formerly dba Diassess Inc, Lucira Health Inc is organized around tackling how infectious diseases can be prevented, diagnosed, and monitored by producing the next generation of rapid DNA testing implemented on smartphones. Effectively, the firm has developed tools that serve to transform smartphones into easy-to-use instruments allowing patients to test their own blood for changes in health quickly and often. The company's technology also has applications in forensics, the chemical industry, and agriculture. In 2018, Lucira Health (Diassess) had been awarded a 5 year, multi million dollar contract by Biomedical Advanced Research and Development Authority - BARDA - to provide professional-use, in-clinic flu diagnostic test and sustains development of the in-home, consumer-focused flu diagnostic test, the latter including the creation of a unique smartphone-based app connecting consumers to treatment options. The funding allowed the firm to take both tests through clinical trials and submit to the U.S. Food and Drug Administration (FDA) for clearance. DiassessÂ’ flu diagnostic technologies gave physicians and consumers an accurate diagnosis within 20 minutes. Beginning with a nasal swab, the sample is inserted into a disposable DNA test. The battery-powered device quickly analyzes the sample and a visual readout indicates either influenza A, B or negative diagnosis. The in-home version uses a smartphone app to directly connect the consumer to treatment options. Clearly, the more recent claim to fame - Nov 2020 - is that the firm has become the first to received FDA approval for a self-administered at-home test for Corvid-19.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
25-49
Revenue Range
2.5M-5M
VC funded?
Yes
Public/Private
Publicly Traded
Stock Info
NASDAQ : LHDX
IP Holdings
25-49

Awards Distribution by Agency

Key People / Management

  Erik Engelson -- President & CEO

  Peter Bacas -- Business Development

  Kelly Lewis Brezoczky -- Exec. VP of Commercialization, Regulatory, Clinical & Bus. Devel.

  Ivan Dimov -- Co-Founder

  Hansgregory Charles Hartmann -- Chief Operating Officer

  Kelly Lewis -- Executive Vice President

  Debkishore Mitra -- Co-Founder and CTO

  Deborah Anne Mitra

  John Waldeisen -- CEO and Co-Founder